UK's Regulatory Agency Backs Pfizer/BioNTech's COVID-19 Vaccine For Youngest Kids

Vandana Singh
1 min read
0
In this article:

  • The Medicines and Healthcare products Regulatory Agency (MHRA) authorized the vaccine - made by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for children aged six months to four years old.

  • This decision was endorsed after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants.

  • The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years.

  • Related: Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages.

  • It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

  • This presentation is designed for this new age group and given at a lower dose than those used in individuals aged 5 to 11 years (3 micrograms compared with 10 micrograms).

  • The Comirnaty COVID vaccine has met the MHRA's required safety, quality, and effectiveness standards to be authorized for use in this age group.

  • Price Action: PFE shares are down 2.38% at $49.53, and BNTX shares are down 3.96% at $160.10 on the last check Monday.

  • Photo via Wikimedia Commons

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories